Project A Phase 1B Multicenter,Open-labelStudy to determine the recommended dose and Regimen of…

Basic data

Title:
A Phase 1B Multicenter,Open-labelStudy to determine the recommended dose and Regimen of Durvalumab(MEDI4736)ceither as Monotherapy or in combination with Pomalidomide(Pom) with or without Low-dose Dexamethasone(Dex) in subjects with relapsed and refractory Multiple Myeloma(RRMM).
Duration:
10/05/2016 to 01/06/2017
Abstract / short description:
A Phase 1B Multicenter,Open-labelStudy to determine the recommended dose and Regimen of Durvalumab(MEDI4736)ceither as Monotherapy or in combination with Pomalidomide(Pom) with or without Low-dose Dexamethasone(Dex) in subjects with relapsed and refractory Multiple Myeloma(RRMM).
Keywords:
Durvalumab
Multiples Myelom

Involved staff

Managers

Faculty of Medicine
University of Tübingen

Contact persons

Faculty of Medicine
University of Tübingen

Local organizational units

Internal Medicine Department II
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

Boudry, Switzerland
Help

will be deleted permanently. This cannot be undone.